Accelr8 Announces First Quarter Results and Reduced Losses

    DENVER, Dec. 19 /PRNewswire-FirstCall/ -- Accelr8 Technology
 Corporation (Amex:   AXK) today reported a loss of $539,330 or $0.05 per
 share on net revenues of $56,219 for the quarter ended October 31, 2006. In
 the comparable three-month period of fiscal 2005, Accelr8 reported a net
 loss of $772,038 or $0.08 per share on net revenues of $86,388. The
 company's fiscal year ends July 31.
     According to David Howson, Accelr8's president, "we've entered an
 intensive biological testing period with the BACcelr8r(TM) rapid bacterial
 analysis system. This has allowed us to ramp down external expenditures as
 we build data sets to support our development. We are expanding our testing
 with recent clinical culture isolates. Then we expect to resume product
 development with the BACcel(TM)-1.0 system for research markets and initial
 clinical trials."
     "As we announced last week at our annual shareholders' meeting, we are
 very pleased with the system's ability to identify major categories of
 highly resistant bacterial strains. We demonstrated identification of the
 important MRSA strain of 'Staph' in less than four hours. We also
 identified a second major category of highly resistant organisms, ESBL
 producers, in the same time period. To the best of our knowledge, no other
 development program or technology has done this before."
     About Accelr8
     Accelr8 Technology Corporation (www.accelr8.com) is a developer of
 innovative materials and instrumentation for advanced applications in
 medical instrumentation, basic research, drug discovery, and bio-detection.
 Accelr8 is developing a rapid clinical pathogen platform, the
 BACcelr8r(TM), based on its innovative surface coatings, assay processing,
 and detection technologies. In addition, Accelr8 licenses certain of its
 proprietary technology for use in applications outside of Accelr8's own
 products.
 
 

SOURCE Accelr8 Technology Corporation